ATEC stock forecast, quote, news & analysis
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma... Show more
Why Alphatec Holdings (ATEC) Stock Is Down -25% in the Last 30 Days
Key Takeaways
- Alphatec Holdings (ATEC) shares have fallen roughly 25% over the last 30 days, with most of the decline concentrated in a single session following its third-quarter 2026 earnings release.
- On October 30, 2026, the stock dropped about 38% after third-quarter revenue of $221.2 million missed expectations and the company lowered its full-year 2026 revenue outlook to approximately $862 million from roughly $882 million.
- The shortfall stemmed mainly from lower biologics attachment and softer thoracolumbar procedure volumes, even as case volumes grew about 20% and new surgeon users increased 25%.
- Surgical hardware revenue rose 17% year over year, and adjusted EBITDA of $38 million grew approximately 46%, with adjusted EBITDA margin expanding to 17.3%.
- Over the trailing three months, ATEC is down about 12%, as an earlier rally toward the high-$11 range was erased by the post-earnings selloff.
- For additional detail on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages for ATEC.
- To complement your own research, consider exploring Trending AI Robots for curated, data-driven trading strategies.
Alphatec Holdings (ATEC) Company Overview and Market Position
Alphatec Holdings, Inc. is a medical technology company focused on the surgical treatment of spinal disorders. Through its wholly owned subsidiaries—Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc.—the company designs and markets spinal implants, access and fixation systems, patient-positioning technology, biologics, and imaging tools. Its expanding InformatiX platform integrates navigation, alignment assessment, and surgical planning, anchored by the EOS imaging system and EOS Insight software.
ATEC positions itself as a procedure-driven innovator rather than a single-product supplier, with a stated vision of becoming the "Standard Bearer in Spine." Investors follow the stock closely because of its fast-growing surgeon base, procedural-volume momentum, and improving profitability, balanced against a still-narrowing GAAP loss and competition from larger orthopedic and spine-focused peers.
Alphatec Holdings (ATEC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ATEC has declined roughly 25%, moving from about $10.72 to approximately $8.09. The move was not gradual: the stock had climbed into the high-$11 range in late October before falling roughly 38% in a single session on October 30, 2026, closing near $7.04 after reporting third-quarter results. Shares have since partially recovered into the low-$8 range.
Over the trailing quarter, the picture is less severe but still negative. From the low-$9 area in early August, ATEC is down about 12%. The quarterly trend reflects a multi-week advance driven by strong surgical hardware growth and margin expansion, followed by a sharp repricing once the company trimmed its revenue guidance.
What Drove ATEC Stock Price in the Last 30 Days
The dominant catalyst was the third-quarter 2026 earnings report released after the market close on October 29, 2026. Total revenue of $221.2 million rose 13% year over year but came in below analyst expectations of roughly $225 million, and adjusted earnings per share of $0.09 also fell short of consensus. Management attributed the shortfall primarily to lower biologics attachment, with biologics revenue declining about $1 million year over year and revenue per case down about 5%.
The company lowered its full-year 2026 revenue guidance to approximately $862 million from roughly $882 million, citing lower biologics attachment, softer thoracolumbar procedure volumes, and a temporary international supply constraint. The guidance cut, coming only a quarter after management reaffirmed the prior outlook, amplified investor disappointment. Analyst reactions compounded the pressure: Needham lowered its price target from $14 to $12 while maintaining a Buy rating, and BMO Capital downgraded the stock to a neutral rating. Broader weakness in technology and growth equities also weighed on sentiment during the same period.
What Drove ATEC Stock Performance Over the Last Quarter
The quarter was defined by two opposing forces. Through September and October, ATEC rallied on sustained operational momentum: surgical hardware revenue rose 17% in the third quarter, case volumes grew about 20%, and net new surgeon users increased 25%. Adjusted EBITDA of $38 million expanded roughly 46% year over year, and the company generated its fifth consecutive quarter of positive trailing twelve-month free cash flow while repaying its remaining 2026 convertible notes.
That advance was unwound by the late-October guidance reduction, which focused investor attention on the biologics shortfall and a softer market for certain spine procedures. The result was a sharp de-rating that left the stock lower over the trailing three months despite otherwise solid underlying growth in its core hardware franchise.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader platform that spans hundreds of bots trading thousands of tickers. Rather than displaying every available strategy, the section surfaces the top-performing and most relevant bots, making it easier to identify approaches aligned with current market conditions. The bots vary widely in strategy, timeframe, and performance metrics, so investors can compare options that range from short-term momentum to longer-horizon approaches. For those seeking a systematic complement to manual research, the page offers a useful starting point for evaluating data-driven trading tools.
ATEC Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. The next quarterly report will be a key test of whether biologics attachment and revenue per case stabilize, which management has identified as a priority. The company's updated full-year 2026 outlook calls for roughly $789 million in surgical revenue, about $73 million in EOS revenue, and approximately $137 million in adjusted EBITDA, alongside positive free cash flow expectations.
Balance-sheet resilience also warrants attention, given that ATEC ended the third quarter with about $80 million in cash and roughly $135 million in total liquidity. The softer thoracolumbar procedure environment the company cited will be tested against results from larger spine and med-tech peers such as Globus Medical (GMED) and Medtronic (MDT). Finally, resolution of the temporary international supply constraint, analyst rating revisions, and any developments related to the securities investigation that followed the guidance cut could influence sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATEC's RSI Indicator dives oversold zone
The RSI Oscillator for ATEC moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 266 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 203 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 73 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-95.212) is very low in comparison to the industry average of (4.142). P/E Ratio (-10.479) is within average values for comparable stocks, (3.291). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices